JPWO2023164618A5 - - Google Patents
Info
- Publication number
- JPWO2023164618A5 JPWO2023164618A5 JP2024550128A JP2024550128A JPWO2023164618A5 JP WO2023164618 A5 JPWO2023164618 A5 JP WO2023164618A5 JP 2024550128 A JP2024550128 A JP 2024550128A JP 2024550128 A JP2024550128 A JP 2024550128A JP WO2023164618 A5 JPWO2023164618 A5 JP WO2023164618A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- sequence
- antibody
- immunoconjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313943P | 2022-02-25 | 2022-02-25 | |
| US63/313,943 | 2022-02-25 | ||
| PCT/US2023/063226 WO2023164618A1 (en) | 2022-02-25 | 2023-02-24 | Cancer treatment with a conditionally active anti-ror2 antibody-drug conjugate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025508819A JP2025508819A (ja) | 2025-04-10 |
| JP2025508819A5 JP2025508819A5 (https=) | 2026-02-16 |
| JPWO2023164618A5 true JPWO2023164618A5 (https=) | 2026-02-16 |
Family
ID=87766744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550128A Pending JP2025508819A (ja) | 2022-02-25 | 2023-02-24 | 抗ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250161472A1 (https=) |
| EP (1) | EP4482870A1 (https=) |
| JP (1) | JP2025508819A (https=) |
| KR (1) | KR20240153580A (https=) |
| CN (1) | CN119095877A (https=) |
| AU (1) | AU2023226070A1 (https=) |
| CA (1) | CA3244077A1 (https=) |
| MX (1) | MX2024010440A (https=) |
| TW (1) | TW202342537A (https=) |
| WO (1) | WO2023164618A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140322234A1 (en) * | 2012-01-03 | 2014-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis and Targeting of ROR2 in Cancer |
| US11673957B2 (en) * | 2015-03-10 | 2023-06-13 | Eureka Therapeutics, Inc. | Anti-ROR2 antibodies |
| WO2017127702A1 (en) * | 2016-01-20 | 2017-07-27 | The Scripps Research Institute | Ror2 antibody compositions and related methods |
| CN116751298A (zh) * | 2016-05-13 | 2023-09-15 | 生物蛋白有限公司 | 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途 |
| BR112022009611A2 (pt) * | 2019-11-18 | 2022-08-09 | Univ California | Anticorpos anti-ror-2 e métodos de uso |
-
2023
- 2023-02-24 WO PCT/US2023/063226 patent/WO2023164618A1/en not_active Ceased
- 2023-02-24 KR KR1020247031146A patent/KR20240153580A/ko active Pending
- 2023-02-24 CA CA3244077A patent/CA3244077A1/en active Pending
- 2023-02-24 EP EP23760970.6A patent/EP4482870A1/en active Pending
- 2023-02-24 JP JP2024550128A patent/JP2025508819A/ja active Pending
- 2023-02-24 AU AU2023226070A patent/AU2023226070A1/en active Pending
- 2023-02-24 US US18/841,038 patent/US20250161472A1/en active Pending
- 2023-02-24 TW TW112106867A patent/TW202342537A/zh unknown
- 2023-02-24 CN CN202380036629.9A patent/CN119095877A/zh active Pending
- 2023-02-24 MX MX2024010440A patent/MX2024010440A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7467526B2 (ja) | 操作された抗体化合物およびこれらの抱合体 | |
| JP2023018157A (ja) | 親水性抗体－薬物コンジュゲート | |
| AU2014373593B2 (en) | Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof | |
| CN108093640A (zh) | 位点特异性抗体-药物缀合物 | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| CN107530442A (zh) | 位点特异性抗体‑药物缀合物 | |
| JP7811217B2 (ja) | 抗ｈｅｒ２抗体－免疫アゴニストコンジュゲート及びその使用 | |
| CN107548306A (zh) | 位点特异性抗体‑药物缀合物 | |
| JP2019524640A5 (https=) | ||
| US20180244789A1 (en) | Anti-prlr antibody-drug conjugates (adc) and uses thereof | |
| KR20200041998A (ko) | 항-egfr 항체 약물 컨쥬게이트(adc) 및 이의 용도 | |
| CN111278462A (zh) | 抗egfr抗体药物结合物(adc)和其用途 | |
| JPWO2023164618A5 (https=) | ||
| US8758758B1 (en) | Post-relapse treatment of CD30 expressing lymphomas | |
| JPWO2022133148A5 (https=) | ||
| JPWO2020065408A5 (https=) | ||
| LI et al. | Development of methods for quality control of an anti-human epidermal growth factor receptor-2-MCC-DM1∗ | |
| JPWO2022261124A5 (https=) | ||
| JP2026510187A (ja) | 抗クローディン－１８．２抗体を含む抗体－薬物コンジュゲート及びがんのためのその治療用途 | |
| WO2024235135A1 (zh) | 大环化合物及其制备方法和用途 | |
| CN120923577A (zh) | 大环类药物偶联物及其制备方法和用途 | |
| EA040940B1 (ru) | Гидрофильные конъюгаты антитело-лекарственное средство | |
| NZ761642B2 (en) | Hydrophilic antibody-drug conjugates |